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Research in context 
1. Systematic review: Articles containing outcomes of Alzheimer’s disease (AD) 
relevant to different stakeholders across the disease spectrum were identified.  
2. Interpretation: Availability of real-world outcomes in a variety of data sources 
across Europe identified through existing catalogs and previous projects, as 
well as relevance of the outcomes per disease stage, were represented in a 
Data Cube. Our results provide a first step toward understanding the European 
real-world AD data landscape in an integrated, visual overview of the available 
data sources across the disease spectrum.  
3. Future directions: Better understanding of the AD real-world data landscape for 
the development of new AD treatments is needed. The list of AD outcomes 
considered relevant by all stakeholder groups should be further refined and 
validated to facilitate the construction of a real-world evidence platform that is 
both relevant and acceptable to the healthcare community. 
 
Word count:  141 (max. 150 words)  
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Highlights 
• Alzheimer’s disease-relevant outcomes were collected for 66 real-world data 
sources <<85 characters>> 
• The ROADMAP Data Cube visualizes available outcomes across different data 
sources <<83 characters>> 
• Stakeholders prioritized quality of life and cognitive and functional abilities <<81 
characters>> 
• Most data sources captured cognitive ability, comorbidities and treatment 
outcomes  <<84 characters>> 
• The least captured outcomes were caregiver and family-related outcomes  
<<72 characters>> 
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Abstract 
INTRODUCTION: The ROADMAP project aimed to provide an integrated overview of 
European real-world data on Alzheimer’s disease (AD) across the disease spectrum.  
METHODS: Metadata were identified from data sources in catalogs of European AD 
projects. Priority outcomes for different stakeholders were identified through systematic 
literature review, patient and public consultations, and stakeholder surveys.  
RESULTS: Information about sixty-six data sources and thirteen outcome domains 
was integrated into a Data Cube. Gap analysis identified cognitive ability, functional 
ability/independence, behavioral/neuropsychiatric symptoms, treatment, comorbidities, 
and mortality as the outcomes collected most. Data were most lacking on caregiver-
related outcomes. In general, electronic health records covered a broader, less detailed 
data spectrum than research cohorts. 
DISCUSSION: This integrated real-world AD data overview provides an intuitive visual 
model that facilitates initial assessment and identification of gaps in relevant outcomes 
data to inform future prospective data collection and matching of data sources and 
outcomes against research protocols.  
 
Keywords: Alzheimer’s disease; real-world data; ROADMAP project; outcomes; 
stakeholders; disease spectrum; gap analysis. 
 
<<Word count = 149; maximum word count = 150>> 
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Abbreviations 
AD  Alzheimer’s disease 
DPUK  Dementias Platform UK 
EHR  Electronic health record 
EMIF  European Medical Information Framework 
 
HCP  Healthcare professional 
IPCI  Integrated Primary Care Information database 
MCI  Mild cognitive impairment 
PPI  Patient and public involvement 
ReDeGi Registry of Dementias of Girona 
ROADMAP Real world Outcomes across the AD spectrum for better care: Multi-
modal data Access Platform 
RWE Real-world evidence 
SIDIAP Information System for Research in Primary Care 
SLR Systematic Literature Review 
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1. Introduction 
There is a diverse landscape of real-world data on Alzheimer’s disease (AD) in Europe. 
Such data are increasingly being used to provide evidence of the effectiveness of new 
AD treatments [1–3]. Use of real-world evidence (RWE) in research may help to 
improve the generalizability of findings by accounting for patient factors such as 
genetics, comorbidities, medication history, and treatment adherence [1,3].  
Identification and characterization of the different European real-world data sources in 
AD provides a first step in understanding the European landscape of RWE and 
identifying data gaps. Several projects, including the European Medical Information 
Framework (EMIF) (http://www.emif.eu) [4,5] and the Dementias Platform United 
Kingdom (DPUK) project (https://www.dementiasplatform.uk), have attempted to 
identify and characterize cohort, electronic health record (EHR), and clinical trial data 
sources in AD. However, an integrated overview of the different data types available 
related to real-world outcomes is lacking. 
The Real world Outcomes across the AD spectrum for better care: Multi-modal data 
Access Platform (ROADMAP) project was a 2-year public–private partnership to 
assess the feasibility of using AD RWE for the development of new AD disease models 
and treatments (http://roadmap-alzheimer.org) [6]. Among the key aims were the 
identification of European AD-relevant real-world data sources and AD-relevant 
outcomes considered a priority by different stakeholder groups (healthcare 
professionals [HCPs], patients, and caregivers). This article describes the integration of 
this information into a Data Cube to provide a three-dimensional overview of how 
different types of European data sources capture key AD outcomes and their relevance 
across the disease stages. Input from stakeholders was gathered to create an overview 
of outcome measures that are considered relevant by the different stakeholders. Thus, 
the Data Cube provides metadata, which are the characteristics of data sources 
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including the types of collected data, protocol features, and governance information, 
mapped against stakeholder preferences. The Data Cube itself does not contain the 
listed databases, neither partly or as a whole. Using the Data Cube, a gap analysis was 
performed to identify missing or partially reported outcomes in the characterized data 
sources. 
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2. Methods 
2.1. Identification of data sources 
Data sources within the ROADMAP Consortium (see Appendix A) and existing 
metadata catalogs from the EMIF project and the DPUK initiative were used as a 
starting point to identify European AD-relevant real-world data sources. Both catalogs 
include detailed information about characteristics of the data sources and the different 
disease-related outcomes that are assessed in each source. The EMIF online catalog 
(https://emif-catalogue.eu) contains metadata on both cohort studies and EHR data 
sources. Cohort studies typically collect observational disease-specific information from 
a group of research participants or patients over a period of time for research 
purposes, whereas EHR data sources typically contain registered information resulting 
from healthcare processes. Information included in the EMIF-AD catalog was 
completed either by data owners or by a member of the EMIF-AD team and 
subsequently checked and completed by data owners. The DPUK catalog is based on 
EMIF catalog ontology but is customized and accessed through the DPUK Data Portal 
(https://portal.dementiasplatform.uk/). Further data sources were also identified through 
the “EU dementia cohort mapping project,” the results of data source mapping projects, 
and knowledge directly provided by ROADMAP Consortium members (including data 
from EHRs and clinical trial control groups).  
 
2.2. Identification of relevant outcomes 
Real-world AD outcomes of relevance to the different stakeholders were identified from 
a systematic literature review (SLR), a series of patient and public involvement (PPI) 
consultations, and a stakeholder survey. The SLR included relevant publications 
regardless of the language the study was published in, the PPI consultations were 
conducted in English, and the survey was undertaken in English. The literature review 
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identified studies that answered the following research question: “Which AD outcomes 
across the spectrum are prioritized by patients, caregivers, and HCPs?” Studies 
published between 2008 and 2017 inclusive were identified across a range of literature 
types. The whole spectrum of AD was considered, from preclinical AD to severe AD 
dementia [7].  
The PPI consultations involved 29 people diagnosed with different forms of mild to 
moderate dementia, caregivers, and HCPs who identified key outcomes they 
considered important indicators of disease progression. People living with dementia 
(n=9, eight women and one man) and people supporting or providing care for people 
with dementia (n=7, five women and two men) were approached through the European 
Working Group of People with Dementia (EWGPWD) with the support of Alzheimer 
Europe. Carers were current family members including spouses and adult children who 
acted as facilitators, or carers supporting the people with dementia. HCPs (n=13) were 
individual professionals working in the field of AD and dementia or with an interest in 
AD and dementia with varying professional backgrounds (ethics, health economics, 
clinical medicine and science, advocacy, and industry). These HCPs were recruited 
through a snowballing approach that originated within the ROADMAP consortium and 
continued through wider professional networks of the individuals already involved. 
Nationalities of the different stakeholders varied and included nine European countries 
and the United States. Outcomes identified in the literature and selected using a 
consensus-based decision making approach were incorporated into surveys. These 
surveys gathered information on the relative importance of these outcomes to multiple 
stakeholder groups, including professionals working in dementia, people with dementia, 
and caregivers. A mixed-methods analytical approach [8,9] was used to compile and 
integrate outcomes identified from the systematic literature review, the PPI 
consultations, and the stakeholder surveys [10] (Table 1). Outcomes at the category 
level were the connecting point for all three methods. For example, cognitive abilities, 
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an outcome category, is made of many granular outcome sub-categories, such as 
memory, language & communication, executive functions, etc. All workstreams raised 
cognitive abilities as a priority outcome category, however at the granular sub-category 
level, differences and nuances arose across the workstreams (e.g. memory loss or 
language difficulties as sub-category). These outcome categories were developed 
through thematic analysis, consensus approaches, previous deliverables within the 
project, data synthesis meetings, and the use of clinical nosology. The survey was 
designed using these specific categories as response options for the questions, and 
the analysis of the PPI consultations and the SLR was undertaken using the categories 
as superordinate coding headings.  Outcomes at the subcategory level were derived 
directly from the data and were allocated to a category through data synthesis 
meetings.   
Outcome prioritization across the workstreams at the category and subcategory for 
individual stakeholder populations was undertaken for the data cube using an inclusive 
approach such that if it was prioritized by any of the workstreams for that stakeholder 
population it was included in the data cube filter for that stakeholder group. Data was 
not equally available across the workstreams for filtering the data cube by both 
stakeholder population and specific stages of disease progression. Stage specific 
prioritization for people with dementia and carers is derived from the PPI consultations 
and the SLR, whereas stage specific prioritization for professionals is derived from the 
SLR and the survey. 
 
2.3. Data integration into a Data Cube 
The list of outcomes from the mixed-methods analytical approach was reviewed and 
refined by ROADMAP consortium members to develop a final consensus-based list 
consisting of main domain headings together with related outcomes. To improve user-
friendliness and ease of completion of the Data Cube, a final selection of outcome 
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domains and outcomes to be included in the Data Cube was made. This selection 
process was supported by the expertise of different Consortium members. Outcomes 
excluded from the Data Cube were those indirectly captured by another outcome (e.g. 
“life as a whole” was excluded since this cannot be directly captured in most cohort 
studies, is not registered in EHR databases or clinical trial data, and is indirectly 
captured by other quality-of-life measures), or those that were difficult to identify and 
conceptualize and therefore unlikely to be directly captured in any of the data source 
types.  
Information about the identified AD data sources, the prioritized AD outcomes with 
measurement tools/scales, and information on their relevance in each disease stage 
were integrated into a three-dimensional Data Cube (Figure 1). The disease stages 
considered were mild cognitive impairment (MCI), mild AD, and moderate-to-severe 
AD. After the outcomes of interest had been identified, a questionnaire was sent to 
custodians of the data sources to determine which of the outcomes were assessed in 
their data source and the measurement tools/scales used. For most data sources, the 
ROADMAP team could extract this information directly from the EMIF-AD or DPUK 
metadata catalogs without contacting the data custodians, since the information in 
these catalogs was provided or checked by the data custodians. Data extraction was 
completed by a ROADMAP Consortium member with expertise in the outcomes 
assessed in the different studies. In the questionnaire, data custodians or ROADMAP 
team members ranked the availability of outcomes in answer to the question: “Are the 
following AD outcomes reflected by any of the measures available in your database?” 
The presence or absence of each outcome for each data source was visualized in the 
form of a “heat map,” which formed the first facet of the Data Cube (Figure 2).  
The second facet of the Data Cube included information on the level of importance of 
each outcome for the different disease stages, derived from HCP ratings. The 
importance of each outcome for each disease stage was again visualized as a “heat 
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map.” The third facet consisted of another “heat map” combining the data sources and 
the different stages of AD. This facet was used as an indicator of how well a data 
source collected information for each disease stage. The user interface for the Data 
Cube allows the user to zoom in on each facet of the rotating cube to view the two-
dimensional heat maps in detail. The Data Cube can be accessed via 
https://datacube.roadmap-alzheimer.org.  
 
2.4. Data gap analysis 
Gaps in the availability of outcomes across the different data sources were evaluated 
by calculating the percentage of data sources containing information on at least one of 
the outcomes within each outcome domain. This was performed separately for the 
three different types of data source and for all data sources combined.  
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3. Results 
3.1. Data sources 
A total of 300 unique data sources in Europe were identified. Of these, questionnaire 
information on outcomes was available from 66 to complete the Data Cube. The 66 
data sources consisted of four clinical trials (placebo data), four EHR databases (one 
each from Denmark and the Netherlands and two from Spain) and 58 cohort studies 
(Appendix B). Of the 58 cohort studies, 30 were identified from the EMIF-AD catalog, 
25 from the DPUK catalog, and three from Consortium data owners (Registry of 
Dementias of Girona [ReDeGi; Spain], Memento [France], and the Gothenburg 
population study H70 [Sweden]).  
 
3.2. Relevant outcomes and stakeholder priority ratings 
A number of outcomes across all three stakeholder groups (HCPs, patients, and 
caregivers) were identified from the systematic literature review. A greater variety of 
outcomes pertaining to caregivers than to HCPs were identified, and there was a 
significant amount of overlap between outcomes relevant to patients and those relevant 
to caregivers (Figure 3).  
The outcomes considered most important across all stakeholder groups were cognitive 
ability, functional ability and independence, and patient quality of life. By disease stage, 
the most important outcomes as rated by HCPs were cognitive ability, functional 
ability/independence, and patient quality of life for MCI; patient quality of life, functional 
ability/independence, cognitive ability, neuropsychiatric symptoms, and quality of 
caregiver’s and family’s lives for mild AD; and quality of caregiver’s and family’s lives, 
patient quality of life, neuropsychiatric symptoms, and behavioral symptoms for 
moderate-to-severe AD. For MCI, cognitive ability was considered very important by a 
large proportion of respondents, but the importance of this outcome domain decreased 
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as disease severity increased. Functional ability/independence showed a similar 
pattern. Results of medical investigations also declined in importance with disease 
severity. Conversely, behavioral and neuropsychiatric symptoms and quality of 
caregiver’s and family’s lives increased in importance with disease progression. Patient 
quality of life and significant disease-related life events received a large share of votes 
at all disease stages. There was little evidence addressing the opinions of patients and 
caregivers about important outcomes in the later stages of AD. 
 
3.3. Data gap analysis 
In general, most of the data sources had at least some information on the different 
outcome domains (Figure 2). When the three types of data source were combined, 
outcomes collected the most (>80% of the data sources) were cognitive ability, 
comorbidities, and therapeutic treatment. Outcomes collected the least (<30% of data 
sources) were functional and structural neuroimaging biomarkers, caregiver use of 
health and social care services, and quality of the caregiver’s and family’s lives. Among 
clinical trial placebo data sources, information on all outcomes was available except for 
quality of the caregiver’s and family’s lives. All EHR registries collected information on 
comorbidities, mortality, significant disease-related life events, treatment, patient use of 
health and social care, and behavioral and neuropsychiatric symptoms. Outcomes not 
collected by the EHR registries were cognitive ability, apolipoprotein E4 genotype, 
functional and structural neuroimaging biomarkers, physical and neurological 
examination, and caregiver use of health and social care services. Among the cohort 
studies, the outcomes most frequently (>75% of studies) collected were cognitive 
ability, comorbidities, treatment, and physical examination. Outcomes collected the 
least (<25% of studies) were quality of the caregiver’s and family’s lives, caregiver use 
of health and social care services, and functional and structural neuroimaging 
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biomarkers. The percentage of data sources with data available for the different 
outcomes identified is presented in Appendix C.  
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4. Discussion 
Overall, the outcome domains most commonly captured were cognitive ability, 
functional ability and independence, behavioral and neuropsychiatric symptoms, 
treatment, and comorbidities and mortality. Fewer data sources collected information 
on significant disease-related life events, medical investigations, use of health and 
social care, and patient quality of life. Data were most lacking on caregiver-oriented 
outcomes, particularly those related to the quality of caregiver’s and family’s lives.  
 
4.1. Data sources 
Different data sources capture different types of information to varying degrees of 
richness and coverage, and no single data source type contains information on all of 
the outcomes across the full AD spectrum. Evidence generation should therefore cover 
several different types of data sources to provide a more complete picture of the data 
landscape.  
In general, the four included EHR databases captured a broad spectrum of data and 
documented actual clinical care, but this information often lacked detail specifically for 
AD and was less suitable for investigation of the causes of AD. By contrast, cohort data 
were well structured and detailed, focusing on disease-relevant items; however, they 
covered a limited proportion of the AD patient population. Clinical trial placebo data 
covered most outcome domains, possibly because these studies are usually designed 
to cover outcomes considered important for evaluation of the efficacy and safety of a 
drug. In our work, which covered approximately 25% of over 300 identified data 
sources, the number of clinical trial placebo data sources and EHR databases was 
lower than the number of cohort studies. Mapping of broad EHR databases to the AD-
outcomes questionnaire required a deep knowledge of the data in order to identify 
outcomes present in less obvious measures than the established scales and tests used 
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in research cohorts and randomized controlled trials (RCTs). This limited the number of 
mapped EHRs in our project. Nevertheless, we believe that our work provides a good 
reflection of the availability of outcomes in the different data sources. 
 
4.2. Outcomes 
The outcomes considered most important across stakeholder groups were cognitive 
ability, functional ability and independence, and patient quality of life. These outcomes 
were assessed to some degree in the four clinical trial data sources included in our 
analysis, but mapping of additional clinical trial data sources is needed to verify this. In 
a recent review by Webster et al. [11], patient quality of life was measured in only 16 of 
125 included clinical trials, and functional ability was measured in less than half of the 
trials. Data capture of these priority outcomes should therefore be encouraged. Several 
of the identified priority outcomes from a stakeholder perspective were qualitative in 
nature (e.g. emotional issues) and therefore differed from those captured in research 
studies and registry databases.  
Although our work has produced a comprehensive list of AD-related outcomes, this is 
only the first step towards understanding these outcomes in the context of different 
stages of the disease for patients, caregivers, and HCPs. Future studies should 
consider the differences between stakeholder-reported priority outcomes and outcomes 
captured in previous studies when choosing tools for outcome assessment. 
Coordinated national and regional efforts may be needed to change the reporting of 
outcomes in routine clinical care to ensure that missing outcomes are documented in 
EHRs and registries, and international collaboration is needed to identify opportunities 
for harmonization.  
 
4.3. Data Cube and data gap analysis 
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The Data Cube was developed to create a visual, comprehensive overview of the 
European RWE landscape in AD and to provide a first step towards an integrated 
overview of the AD data environment. The evolution from a two-dimensional data 
source catalog to a third dimension addressing the relevance of outcomes across the 
disease spectrum should facilitate research studies that are more relevant to those 
impacted by AD. 
By combining information from different data sources, we were able to identify gaps in 
the current collection of AD outcomes. The identification of data gaps that are relevant 
to the various stakeholders and further evaluation of the Data Cube heat maps form an 
important part of data landscape evaluation and should help to inform plans to develop 
supplementary data collection platforms and prospective research protocols to collect 
missing data in the future. Currently, data on outcomes relating to the caregiver and 
family are often lacking and should be assessed in future research. The analysis of 
outcomes available across the different data sources showed that most of the data 
sources had at least some information on the different outcomes. However, data 
sources differ in their suitability for answering specific research questions, and it is 
important to understand the limitations of each type of data source as described above 
in terms of level of detail and specificity. Since it is unlikely that a single data source will 
cover the full spectrum of AD, from pre-symptomatic disease to severe dementia, the 
combining of different data sources may be necessary.  
 
4.4. Strengths and limitations 
An important strength of the work reported here was the starting base of an evidence-
based outcomes list that incorporated multiple stakeholder perspectives. In addition, 
the Data Cube combined disparate information from a wide range of European data 
sources. A limitation of the Data Cube is that it does not include patient-level data, a 
feature that would bridge the gap between the current metadata overview and a future 
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RWE data platform. Another limitation is the reliance on indirect methods to reflect the 
availability of outcomes per disease stage, and further reiterations of the Data Cube 
should consider whether each data source actually records data from individuals in 
specific disease stages.  
With regards to data sources, the main limitation was the under-representation of EHR 
registries and clinical trials. Thus, current data do not provide a representative sample 
of these data sources. However, the few EHR registries included in the Data Cube 
represent several European countries, and variation between different clinical trial data 
sources is often limited by the length of follow-up or high-cost outcomes. A limitation of 
capturing relevant outcomes was the lack of evidence from patients with severe AD. 
Gaining such evidence would be practically and ethically difficult, but it is a gap that 
should be addressed and could be partly bridged by the use of AD-specific registry 
data. Furthermore, although metadata included in the Data Cube were from several 
countries within Europe, the Data Cube might not be generalizable to the whole of 
Europe or countries outside of Europe. However, the Data Cube does provide a clear 
overview of the data outcomes that are generally available and accessible within 
Europe. Challenges of developing the Data Cube were ensuring a balance between 
compactness and sufficient level of detail, creating a user-friendly interface, and 
visualizing the Data Cube in a straightforward and concise manner. Further challenges 
were uncertainty over the accuracy of the information obtained from metadata catalogs 
and variability in responses to questionnaires, with some respondents possibly 
interpreting questions in a slightly different manner.  
 
4.5. Future use of the Data Cube 
Criteria for what constitutes an outcome or outcome measure will require clarification, 
and priority outcomes will need to be further investigated in terms of their validity, 
reliability, and ability to detect meaningful change in the progression of AD. Since 
SYN-01 ROADMAP Final draft Rx 150419 22 of 33 
current outcome prioritization per disease stage was based on HCP ratings only and 
PPI consultations did not gather information on the MCI stage of AD, this will also need 
to be addressed. Considerations for further development and future use of the Data 
Cube include expansion of the number of data sources included, a greater balance 
between different data source types, more direct integration of disease-stage 
information, maintenance of the Data Cube so it remains current, consideration of how 
the Data Cube could be used in future initiatives, exploration of how the Data Cube 
could be combined with subject-level data into a RWE platform, and making the Data 
Cube publicly available. To realize further developments and sustainability, a Data 
Cube Monitoring Committee has been established. We plan to integrate the Data Cube 
with the existing European data sharing initiatives EMIF-AD and DPUK in order for 
researchers to obtain access to the individual-level data of data sources of interest to 
answer potential research questions. These data sharing initiatives have data 
governance and harmonization structures set in place. More information can be found 
on their respective websites (https://emifad.bmd-software.com; 
https://portal.dementiasplatform.uk). 
 
The Data Cube provides an overview of the AD data landscape and can be used as a 
starting point to select appropriate data sources for different types of research 
questions. Questions that could be addressed with data sources included in the Data 
Cube are for example related to cognitive ability or comorbidities, whereas questions 
related to caregiver-oriented outcomes would less likely be able to address given the 
lower availability of the latter in the Data Cube data sources. With that pre-selection, 
researchers are encouraged to visit the EMIF-AD or DPUK Catalogs as well as 
engaging with the data source custodians to find out more detailed information and 
discuss access to the data. Moreover, the Data Cube could be used to identify gaps in 
availability of priority outcomes in different data sources in order to drive future data 
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collection. 
 
4.6. Future RWE generation 
Future data-landscaping and RWE platform development should focus on enhancing 
global collaboration to create a common technical, legal, and ethical model for real-
world research and evidence generation. International, national, and local efforts to 
harmonize database/cohort protocols should also be encouraged. The list of outcomes 
considered relevant by all stakeholders should be further refined and validated to 
facilitate data collection for a platform of European RWE that is both acceptable and 
relevant to the healthcare community and provides information about AD and 
appropriate intervention pathways. Data custodians and patients should be integrated 
into RWE research, not only as data contributors but also as research partners. In 
addition, measures should be implemented to inform them about research results and 
the immediate benefits. Finally, EHR databases and registries should be encouraged to 
include information relevant to specific research programs. 
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5. Conclusions 
A diverse landscape of real-world data is available across Europe for research into AD. 
ROADMAP investigated this landscape and provided an integrated overview of the 
different AD data sources and priority outcomes from the perspectives of different 
stakeholder groups in relation to the different stages of AD, identifying data gaps with 
respect to relevant outcomes. This integrated data overview should enable the 
matching of data sources and relevant outcomes against research protocols, allow the 
development of research studies that are most relevant to those impacted by AD, and 
inform prospective data collection to address outcome evidence gaps.  
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Table 1 AD-related outcome domain categories and related outcomes included 
in the ROADMAP Data Cube.  
Outcome domain category and related outcomes 
Clinical diagnosis 
Subjective memory complaint 
Subjective cognitive complaint 
MCI 
Amnestic MCI 
Non-amnestic MCI 
Dementia 
AD 
Preclinical AD 
Prodromal AD 
Other dementia subtypes 
Vascular dementia 
Mixed dementia 
Frontotemporal dementia 
Dementia with Lewy bodies 
Dementia in other diseases classified elsewhere 
Disease severity and progression 
Staging severity of dementia 
Global improvement/stability/decline 
Cognitive abilities 
Memory 
Language and communication 
Visuospatial ability 
Attention/executive functions 
Intelligence 
Getting lost in own home 
Not recognizing family 
Spatial awareness 
Conscious awareness 
Repeated questions 
Losing the sense of who you are 
Other  
Functional ability and independence 
Clinical judgment on dependence/independence 
Hygiene/bathing 
Dressing 
Toileting 
Transferring 
Walking 
Mobility 
Eating 
Ability to use telephone 
Shopping capacity 
Food preparation 
Housekeeping 
Laundry 
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Transportation/driving capacity 
Responsibility for own medications 
Financial capacity 
Management of everyday technology 
Supervision (preventing dangerous events)  
Communication 
Social engagement 
Behavioral and neuropsychiatric symptoms 
Sleep disturbance/change in sleep–wake patterns/night-time behaviors 
Appetite/eating disorders 
Change in physical activity 
Aggression 
Agitation 
Irritability 
Disinhibition 
Motor disturbances 
Euphoria 
Delusions 
Hallucinations 
Depression 
Anxiety 
Dysphoria 
Apathy/indifference 
Sight 
Emotional issues 
Sensory changes and challenges 
Swallow reflex 
Self-efficacy  
Medical investigations  
Genetic biomarkers 
ApoE4 
Other variants 
Amyloid biomarkers 
CSF 
PET 
Plasma 
Tau biomarkers 
CSF 
PET 
Plasma 
Functional neuroimaging biomarkers 
FDG-PET 
Structural neuroimaging biomarkers 
Whole-brain volume change/atrophy rate 
Hippocampal/medial temporal lobe volume change/atrophy rate 
Ventricular volume change/atrophy rate 
Others 
Other genetic, amyloid, tau, neuroimaging biomarkers 
Physical examination 
Neurological examination 
Assessment by HCP 
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Date and frequency of healthcare appointments 
Date and frequency with which tests are administered 
Use of healthcare and social services 
Health service costs 
Access to information related with the disease 
Patient-related items  
Living accommodation 
Patient healthcare resource use 
Copayment patient 
Caregiver-related items 
Caregiver work status, impact, work days missed  
Caregiver sleep 
Caregiver healthcare resource use 
Personal financial items 
Formal caregiver time 
Informal caregiver time 
Therapeutic treatment 
Starting medication for symptomatic AD 
Starting antipsychotic medication 
Other medications and dosage 
Side effects 
Medical device use 
Other therapeutic interventions 
Significant disease-related life events  
Ability to drive  
Hospitalization 
Institutionalization 
Need for assistance at home 
Need for full-time care 
Safety  
Premature loss of paid employment 
Respite care take-up 
Sick leave 
Welfare support (monetary support) 
Guardianship measures  
Patient QoL 
Self-reported QoL/health utility 
Proxy-reported QoL/health utility 
Impact on relationships and marriage strain/break-up 
Maintaining ability to participate in hobbies 
Quality of the carer’s and family’s lives 
Caregiver perceived burden 
Caregiver comorbidities 
Caregiver’s QoL 
Spouses’ “duty” to care 
Quality of the patient–caregiver relationship 
Caregiver social support 
Mortality and comorbidities 
Mortality  
Comorbidities  
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Stroke  
Cerebrovascular disease  
Coronary heart disease  
Diabetes  
Other vascular diseases  
Obesity  
Parkinson's disease  
Epilepsy  
Other neurological disorders  
Cancer  
Musculoskeletal diseases  
Respiratory diseases  
Genitourinary diseases  
Renal diseases  
Eye-related impairments  
Hearing impairments  
Fractures and other trauma  
Delirium  
Neuropsychiatric disorders 
Frequent infections 
Frailty 
Abbreviations: AD, Alzheimer’s disease; ApoE4, apolipoprotein E4; CSF, cerebrospinal fluid; FDG-PET, 
fluorodeoxyglucose positron emission tomography; HCP, healthcare professional; MCI, mild cognitive 
impairment; PET, positron emission tomography; QoL, quality of life.  
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Fig. 1.  The ROADMAP Data Cube, integrating AD data sources, outcomes, 
and disease stages. 
 
Description: The Data Cube provides a three-dimensional overview of identified AD 
data sources, prioritized AD outcomes, and relevance of the outcomes for the different 
disease stages. The different heat maps visualise the presence or absence of each 
outcome per data source, the importance of each disease stage for the different 
outcomes, and the presence of the different outcomes in each data source and their 
relevance for the different disease stages. Abbreviations: AD, Alzheimer’s disease. 
 
Fig. 2.  Heat map showing the availability of outcome domains and selected 
outcomes in the different data sources.  
 
Description: Shading represents available outcomes, white sections represent an 
outcome that is not available. Abbreviations: ApoE4, apolipoprotein E4; HCP, 
healthcare professional; EHR, electronic health record. 
 
Fig. 3.  Outcomes identified from the systematic literature review, consultations, 
and surveys in relation to their relevance to stakeholder groups. 
 
Description: Venn diagrams showing the identified outcomes relevant to people with 
dementia (top), caregivers (bottom left), and healthcare professionals (bottom right). 
Three different methods were used to identify these prioritized outcomes: systematic 
literature review, consultations, and surveys.  
 
 
